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ABSTRACT
Obesity is associated with elevated levels of serum fatty acids, which accumulate in nonadipose tissues including the liver. Elongation factor 1A-1 (EF1A-1) has previously been
shown to participate in the cell stress and death response of cardiomyocytes to excess
saturated fatty exposure, and in steatotic mouse myocardium. In this thesis, the hypothesis that
the hepatocyte response to fatty acid overload involves EF1A-1 was tested. EF1A-1
expression was induced in the livers of obese mice in association with severe hepatic steatosis,
and in HepG2 human hepatoma cells in response to excess palmitate. Partial translocation of
EF1A-1 from the ER to polymerized actin preceded palmitate-induced cell death. Inhibiting
the elongation function of the protein using a specific inhibitor decreased palmitate-induced
cell death. Results indicate EF1A-1 participates in hepatocyte stress response to saturated fatty
acid excess possibly by mediating changes in protein synthesis related to actin cytoskeleton
remodeling that occur during cell stress.
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1.0 INTRODUCTION
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1.1 Obesity

2	
  

In recent decades, the prevalence of obesity has increased alarmingly, making it a
significant health problem in not only high-income countries, but low and middle-income
countries as well (World Health Organization, 2013). Obesity is defined as abnormal or
excessive fat accumulation that presents a risk to one’s health. A simple measurement of
obesity is the body mass index (BMI), which is calculated by dividing a person’s weight (in
kilograms) by the square of his or her height (in metres) (Pasco et al., 2012). A person with a
BMI greater than 25 is considered overweight, while having a BMI greater than 30 is
generally considered obese (Pasco et al., 2012). The primary cause of obesity is an energy
imbalance between calories consumed and calories expended. According to statistics by The
World Health Organization, obesity has more than doubled since 1980 and today, over 500
million adults are obese worldwide. In Canada, 19.8% of men and 16.8% of women over the
age of 18 have a BMI of 30 or greater according to data collected from 2011 (Statistics
Canada). Obesity has been recognized as an important risk factor for many other conditions
including insulin resistance and type 2 diabetes, hypertension, dyslipidemia, coronary disease,
heart failure, and cancer. A subset of these conditions have been clustered and described as the
metabolic syndrome, which is an insulin-resistant state characterized by various
cardiovascular risk factors (Johnson and Weinstock, 2006). The current unified criteria for
metabolic syndrome takes into account definitions from several international organizations
(Alberti et al., 2009). These criteria are abdominal obesity (increased waist circumference)
plus two of the following characteristics: elevated plasma triglycerides (≥1.7 mmol/l), elevated
fasting blood glucose (≥5.6 mmol/l), decreased high-density lipoprotein (HDL) cholesterol
(<1.03 mmol/l), and elevated blood pressure (≥130/85) (Alberti et al., 2009).
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The majority of cells have limited ability to store excess lipids and to meet their own
fuel needs during extended famine. As a result, specialized cells (adipocytes) have evolved to
store fuel during caloric surplus and distribute lipids in times of need (Unger et al., 2010).
When caloric intake exceeds caloric expenditure, adipocytes initially undergo hypertrophy.
This process triggers adipose tissue paracrine signaling to stimulate adipogenesis in order to
maintain adipose tissue physiological functions during increased energy storage (Bays et al.,
2008). In addition to storing excess calories as triglycerides, adipocytes secrete leptin, a
hormone that signals satiety and reduces caloric intake. Leptin is also responsible for
stimulating fatty acid oxidation in non-adipose tissues (Unger at al., 2010). Eventually, during
conditions of chronic energy overload, the capacity of adipose tissue to expand and function
fails leading to adipocyte dysfunction and uncontrolled lipolysis. This results in elevated
circulating free fatty acids (Muoio and Newgard, 2006). In the liver, hepatocytes package and
secrete excess lipids as very low-density lipoprotein (VLDL), however, chronic exposure of
the liver to circulating free fatty acids (FFA) leads to hepatic insulin resistance. This impairs
hepatic ability to downregulate VLDL production in response to insulin, resulting in VLDL
overproduction and hypertriglyceridemia (Sparks et al., 2012). As a result of this increased
flux of lipid from adipose and liver to peripheral tissues, fatty acids begin to accumulate in
non-adipose locations such as the heart and cardiovascular system, skeletal muscle, kidney,
pancreas (Brookheart et al., 2009) (Figure 1.1). Ectopic lipid accumulation can lead to insulin
resistance in those tissues, inflammation, and apoptosis. The process leading from lipid
accumulation to cell dysfunction and death is termed lipotoxicity, which occurs when cells can
no longer oxidize, safely store or export excess lipid (Unger, 2003). Although dietary lipids
are important for normal biological functions such as membrane biosynthesis, protein
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Figure 1.1 Obesity-related perturbations in metabolic control lead to ectopic lipid
accumulation in multiple organs. A high calorie, high fat diet coupled with inactivity leads
to elevated circulating free fatty acids (FA) and triglycerides (TG). During conditions of
chronic energy overload, the capacity of adipose tissue to expand and function fails. As a
result, lipids accumulate in non-adipose tissues such as the heart and cardiovascular system,
skeletal muscle, kidney, pancreas and liver (indicated by yellow circles). In the liver, chronic
exposure to excess free fatty acids impairs its ability to downregulate VLDL production,
resulting in VLDL overproduction and hypertriglyceridemia. (Adapted from Muoio and
Newgard, 2006)
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modification, intracellular signaling and energy homeostasis, chronic exposure of organs to
elevated concentrations of these lipids leads to organ dysfunction and disease development
(Szendroedi and Roden, 2009).
1.2 NAFLD

Dietary intake of a high calorie and high fat diet coupled with low physical activity
leads to increased circulating levels of free fatty acids and storage of triglycerides in ectopic
organs, including the liver (Szendroedi and Roden, 2009). In the absence of alcohol, lipid
accumulation within the liver is termed nonalcoholic fatty liver disease (NAFLD) and is
considered the hepatic manifestation of the metabolic syndrome. NAFLD describes the
chronic liver disease associated with hepatocyte lipotoxicity and is the most common form of
liver disease affecting both adults and children throughout the world (Erickson, 2009). The
prevalence of NAFLD is increasing due to the increasing rates of obesity, type 2 diabetes, and
metabolic syndrome, all of which are risk factors for the development of NAFLD. It represents
a range of hepatic disease from simple steatosis, which is the accumulation of fat in the liver
and is considered mostly benign, to nonalcoholic steatohepatitis (NASH), characterized by
inflammation and hepatocyte injury (Utzschneirder and Kahn, 2006). NASH can progress to
fibrosis and cirrhosis, and ultimately end stage liver disease. As a result, NAFLD is becoming
an increasingly common cause of liver transplantation as well as a risk factor for the
progression of hepatocellular carcinoma, primarily due to cirrhosis associated with NAFLD
(Shimada et al., 2002; Bullock et al., 2004).
Most patients with fatty liver are asymptomatic and when symptoms do occur, they are
usually non-specific. NAFLD diagnosis remains complex and is usually discovered when a
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condition other than fatty liver is suspected (Schreuder et al., 2008). The main histological
characteristics of NASH, in addition to steatosis, include hepatocyte ballooning, lobular
inflammation and displacement of nuclei to the edge of the cell. The presence of fibrosis

indicates progression of the disease to more severe liver injury (Yeh and Brunt, 2007).
Existing non-invasive diagnostic markers of NAFLD include a set of clinical signs and
symptoms, imaging tests and blood test results (Wieckowska and Feldstein, 2008). Elevated
serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are primarily
observed in patients with NAFLD. These enzymes are located within hepatocytes and are
released into circulation upon liver injury. ALT is located predominantly in the liver, while
AST is also found in other tissues and can be elevated in diseases affecting organs such as the
heart or skeletal muscle (Ozer et al., 2008). However, the reliability of these tests has been
debated due to the fact that levels fluctuate within the normal limit in the majority of patients
with NASH (Adams and Feldstein, 2011). Common imaging techniques to diagnose hepatic
steatosis include ultrasound, computerized tomography (CT) scan and magnetic resonance
imaging (MRI). The most commonly used and least expensive method is ultrasound, while
MRI is the most accurate available imaging technique for quantification of hepatic steatosis
(Schreuder et al., 2008). Nonetheless, no imagining technique is currently capable of detecting
the subtle histological changes, ballooning and inflammation that distinguish hepatic steatosis
from early NASH (Adams and Feldstein, 2011). Liver biopsy remains the only reliable
method to accurately diagnose NASH and to determine the severity of fibrosis and liver
injury.
The cause and progression of NAFLD is complex and not fully understood. However,
insulin resistance is a key feature of ectopic lipid accumulation in the liver. NAFLD is linked
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to both hepatic and adipose tissue insulin resistance in addition to a reduction in whole-body
insulin sensitivity (Utzschneirder and Kahn, 2006). Under normal physiological conditions,
insulin suppresses lipolysis in adipose tissue by inhibiting hormone-sensitive lipase (HSL). In
insulin-resistant states, lipolysis is increased and esterification of fatty acids is inhibited,
resulting in excess flux of free fatty acids to the liver (Trauner et al., 2010). The associated
hyperinsulinemia enhances hepatic de novo lipogenesis through activation of transcription
factors such as sterol regulatory element-binding protein 1c (SREBP-1c), which leads to the
transcriptional activation of lipogenic genes. Furthermore, hyperglycemia induces
carbohydrate response element binding protein (ChREBP) expression, which leads to the
transcriptional activation of additional lipogenic genes (Trauner et al., 2010). The actions of
these two transcription factors lead to activation of enzymes required for the conversion of
excess glucose to fatty acids, which can be esterified into triglycerides (Trauner et al., 2010).
Hepatic steatosis does not always progress to liver injury, indicating that other factors,
including environmental and genetic determinants, are necessary. It is not known why some
individuals with only hepatic steatosis progress to NASH while others do not. Some have
suggested that the accumulation of excess triglyceride (hepatic steatosis) and lipotoxic cell
damage are two responses that occur simultaneously, but independently (Neuschwander-Tetri,
2010).
1.3 Lipotoxicity in Hepatocytes

In the early stages of NAFLD, triglycerides accumulate in hepatocytes. Serum free
fatty acids are elevated in patients with NASH and are correlated with disease progression
(Nehra et al., 2001). There are three main sources of hepatic lipids. Free fatty acids released
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from adipose tissue contribute to the majority of hepatic triglyceride content and play a critical
role in the development of NAFLD (Donnelly et al., 2005). De novo lipogenesis is the second
most important mechanism, while dietary lipid provides about 10% of the hepatic lipid content
(Ibrahim et al., 2011).
Free fatty acids are carried in the circulation bound to albumin, which maintains a low
unbound concentration and allows a higher concentration of free fatty acids to be carried in the
serum (Bradbury, 2006). They can enter the cell by simple diffusion, which is most likely
when circulating, or extracellular, concentrations are very high, or by facilitated transport.

Several fatty acid transport proteins (FATP) and the fatty acid uptake transporter CD36 have
been identified to facilitate uptake (Pohl et al., 2004; Zhou et al, 2008). FATP5 is exclusively
expressed in hepatocytes and is involved with uptake of long-chain (greater than 16 carbons)
free fatty acids (Doege et al., 2006). Once in the cell, free fatty acids may be converted to
triglycerides or undergo β-oxidation at the mitochondria. Triglycerides may be targeted for
export through the production of VLDL particles, or for storage in lipid droplets (Bradbury,
2006). In hepatocytes overwhelmed by excess lipids, in particular saturated fatty acids,
multiple lipotoxic responses are activated resulting in oxidative (Li et al., 2008; Wu et al.,
2008) and endoplasmic reticulum (ER) stress (Wei et al., 2006; Lee at al., 2010), and
ultimately cell death.
1.3.1 Saturated and Unsaturated Fatty Acids
In recent studies, in vitro models of steatosis have been used to study the consequences
of excess lipid accumulation in hepatocytes. These studies typically involve hepatocyte cell
lines or primary hepatocytes treated with high pathophysiological concentrations of saturated
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and unsaturated fatty acids conjugated to bovine serum albumin (BSA). Numerous studies
have demonstrated that saturated fatty acids are more harmful to hepatocytes than unsaturated

fatty acids (Wei et al., 2006; Malhi et al., 2006; Li et al., 2009). This may be due to their
relative inefficiency, compared to unsaturated fatty acids, to be esterified and stored safely as
triglycerides (Listenberger et al., 2003). Treating cells simultaneously with both saturated and
unsaturated fatty acids rescues cells from saturated fatty acid induced apoptosis by diverting
potentially toxic saturated fatty acids to triglyceride formation (de Vries et al., 2007; Akazawa
et al., 2010). Similar observations have been made in animal models of NAFLD suggesting
that saturated fatty acids are damaging to the liver while unsaturated fatty acids are not (Wang
et al., 2006; Li et al., 2009). In leptin-receptor deficient db/db mice fed a methionine and
choline deficient diet, inhibition of diacylglycerol acyltransferase 2 (DGAT2), the enzyme
responsible for esterification of free fatty acids into triglycerides, decreased hepatic steatosis
but elevated hepatic free fatty acids and markers of oxidative stress, inflammation and fibrosis
(Yamaguchi et al., 2007). Mice with hepatic DGAT2 overexpression develop hepatic steatosis
with increased amounts of triglycerides in the liver, but no evidence of liver damage or insulin
resistance (Monetti et al., 2007). Genetic or pharmacological inhibition of stearoyl-CoA
desaturase-1 (SCD1), the enzyme that converts saturated fatty acids to monounsaturated fatty
acids, renders hepatocytes more sensitive to saturated fatty acid-induced apoptosis (Li et al.,
2009). SCD1-/- mice fed a methionine and choline deficient diet accumulated less triglycerides
in the liver compared to wild-type mice but have increased serum free fatty acids, hepatocyte
apoptosis, liver damage and fibrosis. Meanwhile, mice fed a methionine and choline deficient
diet supplemented with oleate, a monounsaturated fatty acid, have less severe liver injury and
apoptosis (Li et al., 2009). Taken together, this suggests that saturated fatty acids are primarily
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responsible for hepatocyte lipotoxicity, while their esterification into triglycerides serves as a
protective mechanism.
1.3.2 ER Stress

The ER is responsible for many cellular functions such as protein synthesis, lipid
synthesis, carbohydrate metabolism, calcium homeostasis and drug detoxification. It also
plays an important role in sensing cellular stress (Fu et al., 2012). Physiological states that
disrupt ER homeostasis create an imbalance between the protein-folding load and the ER’s
capacity to fold proteins, resulting in unfolded or misfolded proteins that accumulate in the ER
lumen (ER stress). To ensure the accuracy of protein folding and to prevent accumulation of
such proteins, eukaryotic cells have developed the unfolded protein response (UPR). The UPR
is a cellular mechanism of inhibiting protein synthesis, increasing protein folding and
increasing ER-associated protein degradation in order to reduce the ER load of unfolded
protein (Kaplowitz et al., 2007). This response is mediated by 3 ER-localized protein sensors:
inositol-requiring enzyme 1α (IRE1α), double-stranded RNA-dependent like ER kinase
(PERK), and activating transcription factor 6 (ATF6) (Fu et al., 2012). Each protein sensor
spans the ER membrane and consists of 3 domains; an ER-luminal domain that senses
unfolded proteins, a transmembrane domain and a cytosolic domain that conveys signals to the
transcriptional or translational apparatus. Under normal physiological conditions, these ER
sensors are associated with the protein folding chaperone glucose-regulated protein 78
(GRP78) (also known as binding immunoglobulin protein, BiP) at their luminal domains and
maintained in an inactive state (Fu et al., 2012). Under conditions of ER stress, GRP78 binds
to unfolded or misfolded proteins, resulting in the release and subsequent activation of the ER
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stress sensors. Following the release of GRP78 from PERK, PERK phosphorylates eukaryotic
translation initiation factor 2 α (eIF2α). Phosphorylation of eIF2α blocks global protein
synthesis while selectively increasing translation of certain mRNAs, such as activating
transcription factor 4 (ATF4). ATF4 promotes apoptosis under severe stress conditions (Lu et
al., 2012). In response to ER stress, IRE1α, by autophosphorylation, initiates expression of the
spliced form of X box binding protein 1 (XBP-1) which activates the transcription of genes

encoding protein folding chaperones and factors that regulate maturation, secretion, and ERassociated protein degradation. Meanwhile, the release of GRP78 from ATF6 allows ATF6 to
translocate to the Golgi apparatus, become cleaved and, similar to XBP-I, activate the
expression of UPR target genes (Fu et al., 2012). If ER stress is prolonged or the UPR is
unable to maintain homeostasis, the ER stress response is initiated, which induces
proinflammatory and proapoptotic pathways. These include activation of c-jun-N-terminal
kinase (JNK) and increased C/EBP-homologous protein (CHOP) expression, which go on to
activate apoptotic pathways (Kaplowitz et al., 2007). ER-stress induced apoptosis can involve
mitochondria, which are recruited by ER signals such as calcium release. Increased expression
of GRP78 and CHOP are characteristic markers of the UPR and the ER stress response,
respectively, and have been shown to be activated under conditions of ER stress in
hepatocytes both in vitro and in vivo (Kaplowitz et al., 2007). In the present study, GRP78 is
used as a marker of the UPR in hepatocytes.
Increasing evidence suggests that ER stress acts as an upstream signal in saturated fatty
acid-induced apoptosis in many cell types, including hepatocytes. Chronic exposure of
cultured hepatocytes to long-chain saturated fatty acids leads to upregulation of UPR and ER
stress markers (CHOP, GRP78, phosphorylated PERK and phosphorylated eIF2α), followed
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by cell death (Wei et al., 2006; Wei et al., 2009; Lee et al., 2010). Mechanisms of saturated

fatty acid-induced ER stress involve release of ER luminal calcium stores and activation of
caspases (Wei et al., 2009; Wei et al., 2007). In vivo, both dietary and genetic models of
hepatic steatosis are associated with upregulation of GRP78, CHOP, phosphorylated PERK
and XBP-1 splicing (Ozcan et al., 2004; Wang et al., 2006; Rahman et al., 2007). Furthermore,
saturated fatty acids can cause direct induction of ER stress by becoming incorporated into the
saturated phospholipid and triglyceride species of the ER membrane, thereby compromising
its structure and function (Borradaile et al., 2006b).
1.3.3 Oxidative Stress
	
  
In addition to ER stress, recent studies have suggested that oxidative stress, indicated
by elevated levels of reactive oxygen species (ROS), is involved in the hepatocyte lipotoxic
response (Li et al., 2008; Wu et al., 2008; Li et al. 2009). ROS are involved in cellular
signaling and homeostasis. However, cell stress, mitochondrial dysfunction and decreased
antioxidant defenses can lead to the overproduction of ROS (Leamy et al., 2013). This can
cause damage to proteins, lipids and DNA, as well as compromise membrane integrity and
organelle function, thereby inducing cell death (Brookheart et al., 2009). The elevated levels
of ROS associated saturated fatty overload in hepatocytes (Li et al., 2008) can be attributed to
various sources. Possible mechanisms include increased expression of cytochrome P450 2E1
(CYP2E1) (the enzyme responsible for the oxidative metabolism of various substrates),
upregulation of NADPH oxidase and increased mitochondrial β-oxidation (Aubert et al.,
2011; Lambertucci et al., 2008; Inoguchi et al., 2000; Cacicedo et al., 2005; Nakamura et al.,
2009). However, the exact role of β-oxidation in promoting lipotoxic ROS accumulation is
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unclear, suggesting that lipids play a complex role in generating ROS, which likely involves
multiple mechanisms (Leamy et al., 2013).
1.3.4 Mitochondrial Dysfunction
Studies using primary mouse hepatocytes and HepG2 cells show that supplementation
with long chain free fatty acids results in Bcl-2-associated X protein (Bax) translocation to the
lysosome, lysosomal permeabilization and activation of cathepsin B, a lysosomal cysteine
protease. This is followed by mitochondrial dysfunction, characterized by mitochondrial

depolarization, cytochrome c release into the cytosol and increased generation of ROS (Li et
al., 2008). Pharmacological inhibition of cathepsin B activation and mitochondrial cytochrome
c release results in decreased free fatty acid induced lipid accumulation and hepatocyte
apoptosis (Wu et al., 2008; Cheng et al., 2009). Moreover, in liver tissue of patients with
NASH, mitochondrial function is impaired, as reflected by impaired mitochondrial respiratory
chain activity (Pérez-Carreras et al., 2003). In addition to these functional abnormalities,
structural changes, such as longitudinal or spherical swelling and the development of
intramitochondrial crystals, are observed in patients with steatohepatitis. It is thought that
intramitochondrial crystals consist of phospholipids, and are perhaps formed in response to
oxidative stress (Caldwell et al., 2009). Taken together, these findings suggest that
mitochondrial dysfunction plays a role in the pathogenesis of lipotoxicity.
ER stress is closely linked to oxidative stress (Zhang and Kaufman, 2008). Oxidative
stress-induced apoptosis requires the release of calcium stores from the ER lumen, which can
lead to ER stress by impairing normal protein-folding functions (Scorrano et al., 2003; Rao et
al., 2004). Together they lead to apoptosis by mitochondrial pathways and caspase activation

	
  

	
  
	
  
	
  
(Wei et al., 2006; Li et al., 2008). A general model for lipotoxic cell death incorporating the
pathways described above is shown in Figure 1.2.
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Figure 1.2 Pathways involved in the cellular response to saturated fatty acid overload.
During exposure to excess saturated fatty acids, cellular capacities to store them as
triglycerides (lipid droplets) and to catabolize them through β-oxidation (mitochondria) are
overwhelmed. The resultant production of ROS, from several potential sources, can induce ER
stress. Palmitate can also be rapidly incorporated into complex lipids in the ER membrane
resulting in dramatic impairment of the structure and integrity of the ER. Both oxidative stress
and altered ER composition and integrity result in the release of ER calcium stores, triggering
apoptotic cell death via mitochondria.

	
  

	
  
	
  
	
  
1.4 Eukaryotic elongation factor 1A-1
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Eukaryotic elongation factor 1A-1 (eEF1A-1) was originally discovered as the factor
responsible for catalyzing the binding of aminoacyl-tRNA (aa-tRNA) to the A-site of the
ribosome during the elongation phase of protein synthesis (McKeehan and Hardesty, 1969),
but is now known to mediate other cellular processes including protein degradation, apoptosis
and cytoskeletal organization (Figure 1.3) (Mateyak and Kinzy, 2010). eEF1A-1 is one of two
isoforms, the other being eEF1A-2, that share 92% amino acid sequence similarity (Kahns et
al., 1998). Both variants have similar functions with regards to peptide elongation, however
they are differentially expressed (Kahns et al., 1998). eEF1A-1 is expressed ubiquitously in
mouse and human tissues (Kahns et al., 1998; Knudsen et al., 1993) while eEF1A-2 is
expressed tissue-specifically in skeletal muscle, brain and heart (Lee et al., 1992; Khalyfa et
al., 2001). The liver exclusively expresses only the eEF1A-1 isoform (Knudsen et al., 1993;
Newbery et al., 2007).
1.4.1 Canonical role of eEF1A-1
eEF1A-1 is activated upon GTP binding through a conformational change that triggers
recruitment of aa-tRNA. This complex then binds to the A-site of the ribosome, resulting in a
quaternary complex. GTP is hydrolyzed to GDP following correct codon-anticodon interaction
which requires the activity of eEF1B, a guanine nucleotide exchange factor (GEF), to promote
GDP release and reactivation of the protein through passive binding of GTP (Mateyak and
Kinzy, 2010). The phosphorylation status eEF1A-1 has been shown to serve as a regulatory
mechanism for controlling protein synthesis at the elongation phase. For example,
phosphorylation of eEF1A-1 at Ser300 by TGF-β inhibits protein synthesis by disrupting
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Figure 1.3 Canonical and non-canonical functions of eEF1A-1. The canonical function of
eEF1A-1 is to bind aa-tRNA in a GTP-dependent manner and deliver it to the ribosome. The
non-canonical functions include turnover of misfolded proteins, binding and bundling the actin
cytoskeleton as well as other cytoskeletal components, and apoptosis. (Adapted from Mateyak
and Kinzy, 2010)
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binding to aa-tRNA (Lin et al., 2010). eEF1A-1 consists of three domains (I, II and III):

domain I is the GTP-binding domain, domain II associates with the aminoacyl of aa-tRNA and
domain III is primarily involved with binding to actin (Mateyak and Kinzy 2010). eEF1A-1 is
abundant within the cell, comprising 1-2% of total cellular protein in normal growing cells
(Ejiri et al., 2002). However, cellular levels of eEF1A-1 are not rate limiting for protein
synthesis (Condeelis, 1995). Its high cellular concentration and proximity to the ribosome
suggests a role for eEF1A-1 in the control and accuracy of peptide elongation. This is
supported by data that eEF1A-1 plays a role in the quality control of newly-synthesized
proteins by binding nascent or unfolded proteins that are no longer associated with the
ribosome, but not to correctly folded proteins (Hotokezaka et al., 2002). eEF1A-1 was
identified as a factor required for the degradation of N alpha-acetylated proteins (Gonen et al.,
2004) and has been shown to bind damaged nascent proteins that are ubiquinated to facilitate
their delivery to the proteasome (Chuang et al., 2005). Studies investigating the intracellular
localization of eEF1A-1 indicate it is predominantly localized in the cytosolic compartment
associated with endoplasmic reticulum, and specifically ribosomes (Hayashi et al., 1989;
Minella et al., 1996; Didichenko et al., 1991).
1.4.2 Association with the Cytoskeleton
In addition to its function in peptide elongation, recent studies have presented evidence
for a role of eEF1A-1 in cytoskeletal reorganization. eEF1A-1 was originally identified as an
actin-binding protein by Yang et al (1990). In this study, it was shown that eEF1A-1 can bind
the actin cytoskeleton in a reversible manner (Yang et al., 1990). Others have indicated that
eEF1A-1 localizes with F-actin by fluorescence microscopy (Dharmawardhane et al., 1991;
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Collings et al., 1994). eEF1A-1 regulates the actin cytoskeleton through its G-actin binding
and F-actin bundling activity, and has been demonstrated to alter the rate of actin

polymerization (Gross and Kinzy, 2005; Murray et al., 1996; Doyle et al., 2011). Furthermore,
studies using a genetic screen have identified the specific regions of eEF1A-1 responsible for
actin binding, which are primarily located in domain III. Mutations in these regions lead to
reduced actin binding and disorganization of the actin cytoskeleton (Gross and Kinzy, 2005,
2007; Liu et al., 2002). It has also been suggested that eEF1A-1 functions in microtubule
dynamics. In vitro experiments demonstrate that eEF1A-1 can bundle and stabilize
microtubules (Durso and Cyr, 1994; Moore et al., 1999), while others have indicated it is
involved with the severing of microtubules (Shiina et al., 1994).
1.4.3 Role in Apoptosis
eEF1A-1 has been reported to play an important role in mediating apoptosis. Early
studies in mouse fibroblasts show that eEF1A-1 protein levels correlate with the rate of
apoptosis during conditions of cell stress. In fact, eEF1A-1 overexpression accelerates the rate
of apoptosis (Duttaroy et al., 1998). Both oxidative and ER stress induce its expression and it
plays an important role in mediating apoptosis under these conditions (Chen at al., 2000;
Borradaile et al., 2006a). Furthermore, recent evidence suggests a role for eEF1A-1 in anoikis
(apoptosis due to loss of cell anchorage) (Itagaki et al., 2012). eEF1A-1 overexpression at the
plasma membrane increases susceptibility of fibroblasts to anoikis during serum starvation
conditions, while disrupting the increase in eEF1A-1 at the plasma membrane by small
interfering RNA (siRNA) renders cells more resistant to anoikis (Itagaki et al., 2012). The proapoptotic activity of eEF1A-1 appears to depend on its ability to regulate the cytoskeleton
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(Shiina et al., 1994; Kato et al., 1997; Borradaile et al., 2006a), which undergoes dramatic
changes during apoptosis (Ndozangue-Touriguine et al., 2008).
1.5 Objectives and Hypothesis

Through a genetic screen using a ROSAβgeo retroviral promoter trap in CHO cells to
identify factors that, when disrupted, confer resistance to saturated fatty acid-induced
apoptosis, eEF1A-1 was identified as a mediator of lipotoxic cell death (Borradaile et al.,
2006a). In isolated cardiomyocytes exposed to excess palmitate, eEF1A-1 protein expression
increased in association with oxidative stress, and ER stress. Oxidative stress, ER stress, and
induction of eEF1A-1 all preceded apoptotic cell death. Knocking down eEF1A-1 expression
conferred resistance to palmitate-induced cell death through the prevention of changes in
polymerized actin content that normally precede apoptosis (Borradaile et al., 2006a). In vivo,
eEF1A-1 expression is induced in steatotic myocardium of mice with cardiac-specific
lipotoxicity, in association with upregulation of markers of oxidative and ER stress
(Borradaile et al., 2006a).
Both the heart and the liver are key organs in the metabolism of fatty acids, and are
significantly impacted by the progressive steatosis that occurs during obesity and metabolic
disease (Szendroedi and Roden, 2009). The studies in this thesis extend the previous findings
in cardiomyocytes, outlined above, to hepatocytes and steatotic liver.

Hypothesis: eEF1A-1 protein responds to lipid overload induced stress in hepatocytes and in
the livers of obese mice, and participates in the process of lipotoxicity. Furthermore, the
mechanism of action of eEF1A-1 in promoting cell death involves its ability to regulate the
actin cytoskeleton.
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The specific objectives of this research project are to:
1. Determine whether hepatic eEF1A-1 expression is induced in obese mice, in association
with ER stress.
2. Determine whether eEF1A-1 responds to fatty acid overload, or the direct induction of
oxidative and ER stress in hepatocytes.
3. Assess the localization of eEF1A-1 to the ER and to polymerized actin during lipid overload
conditions.
4. Determine whether targeted knockdown of eEF1A-1 expression confers resistance to
saturated fatty acid-induced cell death, and whether its elongation function plays a role in the
lipotoxic response.

Relevance to Disease
As discussed previously, eEF1A-1 responds to lipid overload and has been identified as
a key factor in mediating lipotoxic cell death (Borradaile et al., 2006a). NAFLD associated
with obesity is becoming an increasingly prevalent condition and further studies are required
to better understand its cause and progression. It is not yet known whether eEF1A-1 plays a
role in the hepatocyte lipotoxic response. Understanding whether eEF1A-1 plays a significant
role in mediating lipotoxicity in the liver will provide insight into the pathways involved in
this complex disease. This study could have implications for developing therapeutic targets to
slow the progression of NAFLD.

	
  

	
  
	
  
	
  

2.0 MATERIALS AND METHODS
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2.1 Mice
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Studies were performed in accordance with the Canadian Guide of the Care and Use of
Laboratory Animals and were approved by the Western University Animal Care Committee.
Five-week old male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) were fed ad
libitum a chow diet (4% calories from fat, TD8604: Harlan Teklad, Madison, WI) or a high fat
Western diet (42% of calories from fat plus cholesterol (0.05% wt/wt), TD96125; Harlan
Teklad) for 16 weeks. Five week old male 129SvEv were fed ad libitum a chow diet or high
fat Western diet for 15 weeks as described above. Six week old male C57BL/6J mice and
leptin-deficient (ob/ob) mice were maintained on AIN-76A Semi-Purified Diet (Harlan
Teklad) for 4 weeks. Food intake was measured daily and body weight was measured
biweekly. Plasma triglycerides and total cholesterol were determined by enzymatic,
colorimetric assays with reagents obtained from Roche Diagnostics. Blood glucose was
determined using an Ascensia Elite glucometer (Bayer Healthcare, Toronto, Canada). Plasma
insulin was measured using ultrasensitive mouse-specific enzyme-linked immunosorbent
assays (ELISA) (Alpco Diagnostics, Windham, NH). Total liver lipids were extracted from 1.0
g sections of liver that had been obtained at sacrifice and stored at -80 °C. Free cholesterol,
cholesterol ester and triglycerides from chloroform extracts of liver tissue were determined by
enzymatic, colorimetric assays using reagents obtained from Roche Diagnostics and Wako
Diagnostics. All plasma and liver lipid measurements were performed through the Metabolic
Phenotyping Laboratory in Robarts Research Institute. For analyses of hepatic protein
expression, livers were harvested, snap frozen in liquid nitrogen, and tissue homogenates were
prepared in radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitors.
eEF1A-1 and GRP78 levels from 20 µg of tissue homogenates were determined by
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immunoblotting as described below. Bands were quantified by densitometry and normalized to
actin.
2.2 Cell Culture
HepG2 cells were obtained from the American Type Culture Collection (Rockville,
MD) and grown on 100 mm culture dishes at 37°C and 5% CO2. Cells were maintained in 10

ml of Eagles minimum essential medium (EMEM) (Lonza Biowhittaker) with 10% fetal
bovine serum (FBS), 2 mM L-glutamine, 50 IU/ml penicillin, 50 µg/ml streptomycin and 0.5
µg/ml fungizone (Life Technologies). Cells were split (1:6) on a 7 day cycle using trypsinEDTA. For experiments, cells were plated in 6-well (35 mm), 12-well (18 mm) or 24-well
culture plates (Falcon).
For fatty acid treatments, media was supplemented with 0.25 - 1.0 mM palmitate,
oleate or a combination of palmitate and oleate (40:60 ratio). The concentrations of fatty acids
used reflect high physiological to pathophysiological concentrations, as would be observed
during obesity, metabolic syndrome, and type 2 diabetes. The 40:60 ratio of palmitate to
oleate is reflective of the saturated to unsaturated fatty acid composition of North American
(Westernized) diets, and is maintained in circulating postprandial lipoprotein compositions
(Gordon, 1960; Soriguer et al., 2009) For preparation of fatty acids, 20 mM solution of either
palmitate or oleate in 0.01 M NaOH was heated to 70°C for 30 min. 1 N NaOH was added
dropwise to facilitate solubilization. Fatty acids were complexed to 30% fatty acid free bovine
serum albumin (BSA) (Sigma) at a fatty acid to BSA ratio of 2:1. The complexed fatty acids
were added to cell culture media to achieve a fatty acid concentration of 0.25 - 1 mM. BSA
supplemented medium was used for control conditions.

	
  

	
  
	
  
	
  
2.3 Immunoblot Analyses
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Whole cell lysates were prepared using RIPA buffer (150 mM NaCl, 1.0% IGEPAL®
CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris-HCl, pH 8.0) (Sigma)
supplemented with protease inhibitors and total cellular protein was quantified using the
Pierce Bicinchoninic Acid (BCA) Protein Assay Kit (Thermo Scientific, Rockford, IL).
Lysates were centrifuged for 2 minutes at 14 000 rpm (20 800 gav) to eliminate insoluble
material. Ten µg of whole cell lysate protein was diluted 1:1 with 2X Laemmli sample buffer
(LSB) containing β- mercaptoethanol and heated to 100°C for 5 minutes. Samples were
resolved by 10% SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to a 0.45
µM nitrocellulose membrane using a semi-dry transfer apparatus. Membranes were incubated
in 1% blocking buffer for 1 h. eEF1A-1 was detected following an overnight incubation at 4°C
with a 1:7500 dilution of anti-eEF1A-1 mouse monoclonal antibody (Cell Signaling
Technology), and a 1 h incubation with a 1:5000 dilution of a horseradish peroxidase (HRP)conjugated polyclonal anti-mouse antibody (Santa Cruz Biotechnology). GRP78 was detected
following an overnight incubation with a 1:1000 dilution of anti-GRP78 rabbit polyclonal
antibody (Sigma) and a 1 h incubation with a 1:5000 dilution of HRP-conjugated polyclonal
anti-rabbit antibody (Santa Cruz Biotechnology). Actin was detected following an overnight
incubation with a 1:2000 dilution of anti-actin rabbit polyclonal antibody (Sigma) and a 1 h
incubation with a polyclonal anti-rabbit HRP secondary antibody, as described above.
Membranes were washed 3 times for 5 min with Tris-buffered saline and 0.1% Tween-20
(TBS-T) following incubation with primary and secondary antibodies. Blots were incubated
with Enhanced Chemilumniscence Reagents (Thermo Scientific, Rockford, IL) for 1 min and
exposed on film. Bands corresponding to actin ran between the 37 and 50 kD reference bands
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of the Precision Plus Protein All Blue Standards (Biorad), bands corresponding to eEF1A-1
ran beside the 50 kD reference band, and bands corresponding to GRP78 ran beside the 75 kD
reference band. Bands were quantified by densitometry using Quantity One 1-D Analysis
Software (Biorad) and normalized to actin.
2.4 Cell Death
Apoptosis and cell death were assessed by Alexa Fluor 488 annexin V staining and
membrane permeability to propidium iodide, respectively, using the Dead Cell Apoptosis Kit
(Molecular Probes). Following 48 h incubations with various treatments, cells were washed in
cold phosphate-buffered saline (PBS) and harvested by trypsinization. 1X annexin-binding
buffer was prepared by adding 1 mL 5X annexin binding buffer to 4 mL deionized water, and
100 µg/mL working solution of propidium iodide (PI) was prepared by diluting 1 mg/mL PI
stock solution in 45 µL 1X annexin-binding buffer. Cells were centrifuged and resuspended in

1X annexin-binding buffer at a density of 1 x 106 cells/ml. After adding 2.5 µl Alexa Fluor 488
annexin V and 2 µl PI to each 200 µl of cell suspension, cells were incubated at room
temperature for 15 minutes in the dark. Samples were analyzed by flow cytometry with
quantification of 104 cells/sample. Apoptotic cells were defined as annexin V positive and PI
negative, indicating an intact plasma membrane. Dead cells were defined as annexin V
positive and PI positive or PI positive alone, while live cells were negative for both annexin V
and PI. Fluorescence emission was measured at 530 nm and >575 nm using 488 nm excitation.

	
  

	
  
	
  
	
  
2.5 Immunofluorescence Confocal Microscopy
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HepG2 cells were plated on cover glass slides in 6-well plates and allowed to adhere
overnight. Once at 70-80% confluence, cells were incubated for 6 h with growth media
containing BSA alone, 1.0 mM palmitate, oleate, or a combination of palmitate and oleate
(40:60 ratio). Cells were fixed in 4% paraformaldehyde and permeabilized with 0.2% Triton
X-100, then blocked for 15 min in 0.2% BSA and 10% horse serum in PBS. Following the
blocking step, cells were incubated with anti eEF1A-1 monoclonal antibody (1:100 diluted in
blocking buffer) for 1 h, washed 2 times for 5 min in PBS then incubated with a 1:100 dilution
of FITC-conjugated secondary antibody 30 min. For visualization of ER, cells were incubated
with anti-calnexin monoclonal antibody (1:1000) followed by a 1:2000 dilution of secondary
antibody conjugated to Alexa Fluor 546 for 30 min. To visualize lipid droplets, cells were
stained with Oil Red O (Sigma Aldrich). Staining solution was prepared fresh on day of use by
dissolving 0.2 g of Oil Red O powder into 40 ml isopropanol. Working solution was prepared
by mixing 30 ml stock solution with 20 ml PBS and filter sterilizing using a 0.22 µm syringe
filter. To visualize polymerized actin (F-actin), cells were incubated with rhodamine
phalloidin for 15 minutes followed by 5 minute washes (repeated 3 times) in PBS. All
coverslips were mounted onto glass slides with mounting media containing DAPI to visualize
nuclei (ProLong Gold Antifade Reagent with DAPI, Molecular Probes). Cells were imaged by
confocal laser scanning microscopy (Zeiss LSM 510 Meta Confocal Microscope) at the
London Regional Cell and In Vitro Molecular Imaging Facility at Robarts Research Institute,
and images were processed with Zeiss LSM 5 Image Browser. Colocalization was quantified
through Image J using Pearson’s correlation coefficient (Rr), which is a standard statistical
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analysis designed to measure the strength of a linear relationship between two variables, in
this case fluorescent intensities from two images (Barlow et al., 2010).
2.6 Subcellular Fractionation

HepG2 cells were plated and grown to confluence in 10 cm dishes and incubated with
BSA or palmitate for 6 h as described previously. Cells were harvested in 250 mM sucrose
and 10 mM Tris HCl containing protease inhibitors and homogenized using a Dounce
homogenizer. The homogenate was centrifuged at 800 x gav for 10 minutes to yield a nuclear
pellet and a post-nuclear supernatant. The supernatant was centrifuged at 10 000 x gav for 10
minutes to yield a mitochondrial pellet and a post-mitochondrial supernatant. The postmitochondrial supernatant was layered over a 1.3 M sucrose cushion and centrifuged at 202
000 x gav for 2.5 hours to yield three distinct fractions: a post-microsomal supernatant
representing cytosol, a fraction at the interphase of the sucrose cushion representing smooth
microsomes and the Golgi apparatus, and a pellet fraction representing rough microsomes.
RIPA buffer containing protease inhibitors was added to the smooth and rough microsomal
fractions. eEF1A-1 and GRP78 levels from 25 µg of isolated subcellular fractions were
determined by immunoblotting as described above.
2.7 [3H] Leucine Incorporation Assay
HepG2 cells were plated in 24-well plates, grown to 70-80% confluency and treated
with increasing concentrations of didemnin B (up to 200 nM) or DMSO as a control, for 48 h.
Didemnin B was obtained from the Open Chemical Repository of the Developmental
Therapeutics Program at the National Cancer Institute (NIH). Following treatment, 1 µL [3H]
leucine was added to 250 µl growth medium per well for a specific activity of 500 kBq/ml.
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Cells were incubated at 37°C for 60 min. Cells and culture media (for quantification of

synthesis of both non-secreted and secreted proteins) were precipitated with cold 1 M
trichloroacetic acid (TCA) for 60 min. A sample for total protein quantification was taken
prior to precipitation. Samples were centrifuged at 12 000 rpm for 2 min at 4°C and washed 3
times in 100% ethanol by resuspension and centrifugation. The pellet was solubilized in 1 N
NaOH and samples were prepared for scintillation counting. Counts measured represented the
amount of [3H] leucine incorporated into newly synthesized protein, and were expressed
relative to total protein for each sample.
2.8 MTT Assay
HepG2 cells were plated at 50 000 cells per well in a 96-well plate and treated with
increasing concentrations of didemnin B up to 200 nM or DMSO as a control for 48 h. Cell
viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) cell-metabolism assay. MTT solution was prepared by dissolving 5 mg
MTT/ml in sterile PBS at room temperature and filter sterilizing using a 0.2 µm syringe filter.
Following treatment, 10 µl MTT was added to each well and incubated for 3 h at 37°C.
Formazan crystals formed by the reduction of MTT were dissolved in extraction buffer
consisting of 50 ml dimethylformamide (DMF), 50 ml ddH20 and 20 g SDS adjusted to pH 7.4
and incubated overnight. Absorbance was quantified spectrophotometrically at a wavelength
of 570 nm. The intensity of the coloured product formed is directly proportional to the number
of live cells present in each sample.
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2.9 Transfections

Human eEF1A-1 cDNA sequence was used to design siRNA template oligonucleotides
using the Ambion siRNA Target Finder tool. No commercially available pre-designed RNAi
reagents are currently available that specifically target eEF1A-1. Hairpin siRNA template
oligonucleotide sequences predicted to reduce eEF1A-1 expression were used to generate
pSilencer 2.1-U6 expression vectors (Ambion) that were transfected into HepG2 cells.
Transfected cells were selected by growth in 500 µg/ml hygromycin for 7 days. Two target
sequences that were predicted to generate knockdown of protein expression were selected,
however,

following

immunoblot

analysis

only

one

sequence,

5’-

AAGTCTGTAATGAAGTGTTAT-3’, was determined to efficiently reduce eEF1A-1
expression. Cells expressing shRNA targeting this sequence were used for subsequent
experiments. A control-shRNA expressing population was generated using scrambled shRNA
constructs encoding no known target in which eEF1A-1 expression was not reduced.
2.10 Statistical analysis
Statistical analyses were performed using either Student’s t-Test or a one-way
ANOVA followed by Tukey’s post hoc test. Differences in means were considered
statistically significant at p < 0.05. Immunoblots were quantified by densitometry using
Quantity One 1-D Analysis Software (Biorad) and normalized to actin. GraphPad Prism
version 5.0 software was used for all statistical analyses and generation of graphs.

	
  

	
  
	
  
	
  

3.0 RESULTS
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3.1 eEF1A-1 and GRP78 protein are increased in the liver of some mouse models of
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obesity with hepatic steatosis
eEF1A-1 has been identified as a key mediator of lipotoxic cell death through a genetic
screen in CHO cells (Borradaile et al., 2006a). In vivo, eEF1A-1 expression is induced in
steatotic myocardium of mice with cardiac-specific lipotoxicity, in association with
upregulation of markers of oxidative and ER stress (Borradaile et al., 2006a). In the present
study, eEF1A-1 protein is increased in some mouse models of obesity, in association with ER
stress. In obese, leptin deficient ob/ob mice maintained on AIN-76A diet for 4 weeks, hepatic
eEF1A-1 and GRP78 protein increased 1.32 and 2.12-fold, respectively, compared to control
C57BL/6J mice (Figure 3.1 A). In these mice, liver triglycerides and plasma insulin were
elevated 8.9 and 30-fold, respectively (Table 3.1). In C57BL/6J mice maintained on a Western
diet for 16 weeks, a 1.39-fold increase in hepatic GRP78 expression was observed while
eEF1A-1 expression remained unchanged (Figure 3.1 B). These data suggests eEF1A-1
expression may increase under conditions of hepatic stress caused by severe steatosis and
insulin resistance. Interestingly, eEF1A-1 and GRP78 protein are decreased (17% and 42%,
respectively) in the livers of 129SvEv mice maintained on a Western diet for 15 weeks
compared to chow-fed control mice (Figure 3.1 C). Unlike the other mouse models of obesity,
these mice were not hyperinsulinemic (Table 3.1). Increases in body weight, epididymal fat
weight, plasma cholesterol, liver triglyceride and liver cholesterol ester were observed in both
genetic and diet-induced models (C57BL/6J and 129SvEv) of obesity (Table 3.1). Together,
data from C57BL/6J and 129SvEv mice fed a Western diet, as well as obese, leptin deficient
ob/ob mice demonstrated positive correlations between eEF1A-1 protein expression with both
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Figure 3.1 eEF1A-1 and GRP78 protein are increased in some mouse models of obesity
with hepatic steatosis. eEF1A-1 and GRP78 protein were detected in whole tissue
homogenates from livers of (A) 6 week old wild type (C57BL/6J) or leptin-deficient (ob/ob)
mice maintained on AIN-76A diet for 4 weeks, (B) 5 week old C57BL/6J mice maintained
on a chow or western diet for 16 weeks, (C) 5 week old 129SvEv mice maintained on a
chow or western diet for 15 weeks. eEF1A-1 and GRP78 protein were detected by
immunoblotting and quantified by densitometry for 6 chow and 6 western diet fed mice (for
both 129SvEv and C57BL/6J strains) and 8 wild type (C57BL/6J) and 8 ob/ob mice. Data
are expressed relative to actin. Representative blots are shown. All data are expressed as
means ± SEM, * p < 0.05
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Table 1 Parameters of metabolic disease in 3 mouse models of obesity and hepatic
steatosis. Mice were maintained as described for Figure 1. Body weight, epididymal fat
weight and liver weight were determined at sacrifice. Blood glucose was measured by
glucometer. Plasma and liver lipids were measured enzymatically. Plasma insulin was
measured by ELISA. Data are expressed as mean ± SEM, *p < 0.05 for 129SvEv or C57BL/
6J mice fed a chow diet compared to western diet and ob/ob mice compared to wild-type
C57BL/6J mice.
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liver triglyceride (Figure 3.2 A) and plasma insulin (Figure 3.2 B), and between GRP78
expression and plasma insulin (Figure 3.2 D).
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Figure 3.2 Hepatic eEF1A-1 expression correlates with liver triglyceride content and
plasma insulin concentration. Liver triglycerides and plasma insulin are plotted against
GRP78 and eEF1A-1 expression for 3 mouse models of obesity. 5 week old 129SvEv mice
were maintained on a chow or western diet (WD) for 15 weeks, 5 week old C57BL/6J mice
were maintained on a chow or western diet for 16 weeks and 6 week old wild type (C57BL/
6J) or leptin-deficient (ob/ob) mice were maintained on AIN-76A diet for 4 weeks.
Triglycerides from chloroform extracts of liver tissue were quantified enzymatically, and
plasma insulin was quantified by ELISA. eEF1A-1 and GRP78 protein were detected by
immunoblotting and quantified by densitometry for 6 chow and 6 western diet fed mice (for
both 129SvEv and C57B/6 strains) and 8 wild type (C57BL/6J) and 8 ob/ob mice. Protein
are expressed relative to actin. Significant correlations (p < 0.05) are indicated with r2 value.
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3.2 eEF1A-1 protein is rapidly induced in response to saturated fatty acid overload-
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induced ER stress in HepG2 cells, an event that precedes cell death
Having determined that eEF1A-1 is increased under conditions of severe hepatic
steatosis and insulin resistance in mice, we set out to characterize and modulate expression
levels of eEF1A-1 in an in vitro model to determine the role of this protein in the hepatocyte
lipotoxic response. Previous studies showed that levels of eEF1A-1 increase in CHO cells and
H9c2 rat cardiomyocytes in response to palmitate (Borradaile et al., 2006a). In these cells,
eEF1A-1 expression was rapidly induced (30 minutes and 1 h, respectively) and remained
elevated for 5 h after treatment with palmitate (Borradaile et al., 2006a). For the present study,
we selected HepG2 human hepatoma cells as an in vitro model of hepatocytes. HepG2 cells
are well suited for this application because, like human and rodent liver, and unlike other
hepatocyte lines, they exclusively express the eEF1A-1 variant of eEF1A (Grassi et al., 2007;
Newbery et al., 2007). In HepG2 cells incubated for 6 h with growth media containing either
palmitate (1.0 mM) or a combination of palmitate and oleate (1.0 mM, 40:60 ratio), eEF1A-1
protein increased 1.24-fold and 1.72-fold, respectively. In contrast, incubation with 1.0 mM
oleate decreased eEF1A-1 expression by 16% (Figure 3.3 A). Changes in eEF1A-1 content
were accompanied by similar changes in GRP78 content in palmitate treated cells, indicating
the onset of ER stress under these lipid overload conditions (Figure 3.3 B).
In addition to fatty acid induced cell stress, eEF1A-1 has been shown to be directly
induced in response to oxidative and ER stress (Chen et al., 2000; Borradaile et al., 2006a). For
the present study, H2O2 was used to induce oxidative stress and tunicamycin was used to induce
ER stress. Tunicamycin inhibits protein glycosylation and subsequent protein folding, and is
widely used as an inducer of ER stress and the UPR (Lee, 2001). An increasing trend in
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Figure 3.3 eEF1A-1 expression is increased in HepG2 cells during fatty acid overload
induced ER stress. HepG2 cells were incubated for 6 h with growth media containing BSA
alone, palmitate (PA), oleate (OA) or a combination of palmitate and oleate (40:60 ratio) at
concentrations of 0.25, 0.5 and 1.0 mM. All fatty acids were conjugated to BSA at a molar
ratio of 2:1. (A) eEF1A-1 and (B) GRP78 protein were detected in whole cell lysates by
immunoblotting. All data were quantified by densitometry and normalized to actin.
Representative blots are shown beside each graph. Fatty acid treatments are compared to the
lowest respective concentration (0.25 mM). Data are expressed as mean ± SEM for 3-6
independent experiments, *p < 0.05.
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eEF1A-1 expression was noted following incubation with 1.0 µg/ml tunicamycin for 6 h. In
addition, eEF1A-1 protein increased 1.97-fold in cells treated with 2.5 mM H202, indicating that
eEF1A-1 expression in hepatocytes also responds to direct induction of oxidative stress (Figure
3.4 A). GRP78 expression increased 2.41-fold following treatment with tunicamycin (Figure
3.4 B).
Saturated fatty acids are known to trigger cellular stress responses leading to apoptotic
cell death in hepatocyte cell lines and primary hepatocytes, as well as in other cell types (Wei
et al., 2006; Li et al., 2009). Consistent with these earlier studies, treatment of HepG2 cells
with 1.0 mM palmitate for 48 h resulted in a 2.24 fold increase in the proportion of cell death
compared to BSA treated cells (Figure 3.5). No difference in cell death was observed in oleate,
or a combination of palmitate and oleate treated cells.
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Figure 3.4 eEF1A-1 expression is increased in HepG2 cells in response to direct
induction of oxidative or ER stress. HepG2 cells were incubated for 6 h with 2.5 mM H202
or 1.0 µg/ml tunicamycin. Control cells were incubated for 6 h with water or DMSO,
respectively. (A) eEF1A-1 expression and (B) GRP78 expression were detected at the
protein level in whole cell lysates by immunoblotting. All data were quantified by
densitometry and normalized to actin. Representative blots are shown below each graph.
Tunicamycin and H202 treated cells are compared to control. Data are expressed as mean ±
SEM for 3-6 independent experiments, *p < 0.05.
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Figure 3.5 Palmitate induces lipotoxicity in HepG2 cells.
Confluent HepG2 cells were incubated for 48 h with growth media containing BSA alone,
1.0 mM PA, OA or a combination of PA and OA (40:60 ratio). All fatty acids were
conjugated to BSA at a molar ratio of 2:1. Cells were harvested, stained with propidium
iodide, and the proportion of dead cells was determined by flow cytometry. Fatty acid
treatments are compared to BSA control. All data are expressed as mean ± SEM for 4-8
independent experiments, *p < 0.05.
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3.3 Palmitate induces eEF1A-1 colocalization with the actin cytoskeleton
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In addition to its canonical role in peptide elongation, eEF1A-1 is known to participate
in remodeling of the actin cytoskeleton, which undergoes dramatic changes during apoptosis
and cell death (Murray et al., 1996; Ndozangue-Touriguine et al., 2008). eEF1A-1 has also
been reported to associate with lipid droplets and the ER in various cell types (Zhang et al.,
2011; Bouchoux et al., 2011; Chen et al., 2010; Minella et al., 1996). To assess the
localization of eEF1A-1 with the actin cytoskeleton, as well as its association with lipid
droplets and the ER in response to lipid overload, HepG2 cells were treated for 6 h with fatty
acids, fixed, stained, and imaged by confocal fluorescent microscopy, as described in
Materials and Methods.
eEF1A-1 has been identified to associate with lipid droplets in proteomic analyses of
neutral lipid droplets from mouse skeletal muscle and intestinal enterocytes (Zhang et al.,
2011; Bouchoux et al., 2011). However, our experiments indicated no colocalization of
eEF1A-1 with cytosolic neutral lipid droplets in HepG2 cells in either of the fatty acid
treatment conditions (Figure 3.6 C-F). As seen in Figure 3.6 G-H, enlargement of the outlined
area indicates that eEF1A-1 surrounds lipid droplets but does not colocalize with or decorate
these neutral lipid stores.
eEF1A-1 has been found predominantly localized to the ER in fibroblast cells,
particularly in association with ribosomes (Hayashi et al., 1989). Consistent with these studies,
our confocal fluorescent microscopy images indicate that eEF1A-1 colocalizes with the ER in
hepatocytes under basal conditions (Figure 3.7 C-F). Colocalization was quantified through
ImageJ using Pearson’s correlation coefficient (Rr), in order to measure the strength of the
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Figure 3.6 eEF1A-1 does not colocalize with lipid droplets in HepG2 cells. HepG2 cells
were incubated for 6 h with growth media containing BSA alone, 1.0 mM PA, OA or a
combination of PA and OA (40:60 ratio). All fatty acids were conjugated to BSA at a molar
ratio of 2:1. eEF1A-1 and lipid droplets were assessed by confocal fluorescent microscopy.
Cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100 and
incubated with anti-eEF1A monoclonal antibody followed by secondary conjugated to FITC
(green) to visualize EF1A-1 (A). Cells were stained with Oil Red O (ORO) to visualize
neutral lipids (red) (B) and counterstained with DAPI to visualize nuclei (blue). Localization
of eEF1A-1 with lipid droplets was assessed in cells treated with BSA (C), PA (D), OA (E)
and a combination of PA and OA (F). Enlargement of the outlined area in (F) indicate that
no colocalization was observed between eEF1A-1 and cytosolic neutral lipid droplets.
Representative images from 3 independent experiments are shown.
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Figure 3.7 eEF1A-1 colocalization with the ER is decreased during exposure to excess
palmitate. HepG2 cells were incubated for 6 h with growth media containing BSA alone,
palmitate (PA), oleate (OA) or a combination of palmitate and oleate (40:60 ratio) at
concentrations of 0.25, 0.5 and 1.0 mM. All fatty acids were conjugated to BSA at a molar
ratio of 2:1. eEF1A-1 and ER were assessed by confocal fluorescent microscopy. Cells were
fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100 and incubated with
anti-eEF1A monoclonal antibody followed by secondary conjugated to FITC (green) to
visualize EF1A-1 (A). Cells were incubated with anti-calnexin monoclonal antibody
followed by secondary conjugated to Alexa Fluor 546 (red) to visualize ER (B) and
counterstained with DAPI to visualize nuclei (blue). Colocalization of eEF1A-1 with ER
was assessed in cells treated with BSA (C), PA (D), OA (E) and a combination of PA and
OA (40:60 ratio) (F). Colocalized signal is seen in yellow and was quantified using
Pearson’s correlation coefficient (Rr) to assess overlap between signal for eEFIA-1 and
calnexin (G). (H) eEF1A-1 protein levels were detected in cytosolic, smooth microsomal,
and rough microsomal fractions isolated by sequential centrifugations in the absence or
presence of palmitate (8 h treatment). GRP78 and actin were detected to determine the
relative enrichment and contamination of each fraction. Representative blots are shown. All
data are expressed as mean ± SEM for 3 independent experiments, *p < 0.05.
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relationship between fluorescent intensities from two images (Barlow et al., 2010). This value

ranges from -1.0 to 1.0, where 0 indicates random distribution, -1.0 indicates complete inverse
correlation and 1.0 indicates complete positive correlation between fluorescent signals
(Zinchuk and Grossenbacher-Zinchuk, 2009). In our experiments, the Rr for eEF1A-1
colocalization with F-actin or ER ranged from -0.0023 to 0.60 in all treatments tested. In
HepG2 cells incubated for 6 h in the presence of palmitate, a 30% decrease in colocalization
of eEF1A-1 with the ER was observed compared to BSA treated cells (Figure 3.7 G).
Subcellular fractionation of HepG2 cells confirmed that eEF1A-1 is enriched in ER fractions
(Figure 3.7 H).
The decrease in colocalization of eEF1A-1 with the ER in response to excess palmitate
was accompanied by a corresponding increase (2.79-fold) in colocalization of eEF1A-1 with
the actin cytoskeleton (Figure 3.8). Images constructed from a z-series of optical sections
indicated that under basal conditions, F-actin was primarily localized to the basolateral surface
of the cell monolayer while eEF1A-1 was localized apically (Figure 3.8 G). Treatment with
palmitate resulted in increased colocalized signal at the basolateral surface (Figure 3.8 H).
3.4 Inhibition of eEFA-1 elongation function decreases palmitate-induced cell death
To determine whether the peptide elongation function of eEF1A-1 plays a role in the
lipotoxic response, HepG2 cells were incubated with didemnin B, a member of a class of
cyclic depsipeptides produced by ascidians (marine tunicates) that are known to have eEF1A1-dependent inhibitory effects on protein synthesis (Marco et al., 2003). Didemnin B
specifically binds GTP-bound eEF1A-1 at the ribosome and inhibits its release from the
ribosomal A-site, thus attenuating protein synthesis (Marco et al., 2003). HepG2 cells were
treated for 48 h with increasing concentrations of didemnin B, followed by assessment of total
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Figure 3.8 eEF1A-1 colocalization with the actin cytoskeleton is increased during
exposure to excess palmitate. HepG2 cells were incubated for 6 h with growth media
containing 1.0 mM palmitate PA conjugated to BSA (molar ratio 2:1), OA conjugated to
BSA (molar ratio 2:1), a combination of palmitate and oleate (40:60 ratio), or BSA alone.
eEF1A-1 and polymerized actin, and were assessed by confocal fluorescent microscopy.
Cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100 and
incubated with anti-eEF1A monoclonal antibody for 1 h and secondary conjugated to FITC
(green) for 30 min to visualize EF1A-1 (A). Cells were stained with rhodamine phalloidin to
visualize F-actin (red) (B) and counterstained with DAPI to visualize nuclei (blue).
Colocalization of eEF1A-1 with ER was assessed in cells treated with BSA (C), PA (D), OA
(E) and a combination of PA and OA (40:60 ratio) (F). (G) and (H) show images
constructed from a z-series of optical sections of cells treated with BSA and PA,
respectively. Colocalized signal is seen in yellow and was quantified using Pearson’s
correlation coefficient (Rr) to assess overlap between signal for eEFIA-1 and phalloidin (I).
All data are expressed as mean ± SEM 4 independent experiments, *p < 0.05.
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protein synthesis by [3H] leucine incorporation over 1 h (Figure 3.9 A). Concentrations used

were selected based on previous studies of didemnin B in human cancer cell lines (Beidler et
al., 1999). The IC50 for inhibition of protein synthesis was determined to be 80 nM (Figure 3.9
A). Cell viability, measured using the MTT cell-metabolism assay, was not affected at this
IC50 concentration (Figure 3.9 B). In subsequent experiments, cells were treated with 1.0 mM
palmitate in the presence or absence of 80 nM didemnin B for 48 h followed by assessment of
cell death by flow cytometry. Treatment with palmitate in the presence of didemnin B
decreased palmitate-induced cell death (Figure 3.9 C), suggesting that the elongation function
of eEF1A-1 may play a role in the lipotoxic response.

3.5 Modest long-term inhibition of eEF1A-1 expression alters HepG2 morphology
Previous studies showed that knockdown of eEF1A-1 expression in CHO cells and
H9c2 cardiomyocytes conferred resistance to palmitate-induced cell death (Borradaile et al.,
2006a). To extend these findings to hepatocytes, a cell type that, similar to cardiomyocytes, is
affected by lipotoxicity in metabolic disease, we generated two populations of HepG2 cells
with stable expression of shRNA predicted to target eEF1A-1 message. Control cells
expressed an shRNA construct encoding no known target. Upon assessment of the extent of
eEF1A-1 knockdown by immunoblotting, only one population (EF shRNA) was identified as
having significantly reduced eEF1A-1 expression (18%) (Figure 3.10 A). This population was
used for subsequent experiments. Although the reduction of eEF1A-1 expression in EF
shRNA expressing cells is modest, this protein is abundant in cells and represents about 2% of
total cellular protein (Ejiri et al., 2002). Thus small decreases in relative levels of eEF1A-1
reflect large decreases in total protein production. Unlike in H9c2 cardiomyocytes,
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Figure 3.9 Inhibition of eEF1A-1 elongation function decreases palmitate-induced cell
death. HepG2 cells were treated for 48 h with increasing concentrations of didemnin B
(inhibitor of eEF1A-1 elongation function), or DMSO as a control, followed by assessment
of total protein synthesis by [3H] leucine incorporation. The IC50 for inhibition of protein
synthesis was 80 nM. (B) Cells were incubated as described above, followed by incubation
for 3 h with 5 mg/ml MTT. MTT reduction, indicative of cell viability, was quantified
spectrophotometrically at a wavelength of 570 nm. (C) HepG2 cells were incubated for 48 h
with growth media containing 1.0 mM PA conjugated to BSA (molar ratio 2:1) in the
presence or absence of 80 nM didemnin B (IC50). Cells were harvested, stained, and the
proportions of live cells (Ann V- PI-), apoptotic cells (Ann V+ PI-) and dead cells (Ann V+ PI
+)

were determined by flow cytometry. For A and B, data are expressed as percentage of

control ± SEM for 3 independent experiments. For C, data are expressed as mean ± SEM for
4 independent experiments, *p < 0.05 for PA compared to BSA control.
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Figure 3.10 Modest long-term inhibition of eEF1A-1 expression alters HepG2
morphology. HepG2 cell lines were generated expressing either control shRNA against no
known target, or shRNA targeted against eEF1A-1 (EF shRNA) (A). eEF1A-1 protein levels
from whole cell lysates were detected by immunoblotting. All data were quantified by
densitometry and normalized to actin. A representative blot from 5 independent experiments
is shown (A). (B) Control shRNA and EF shRNA expressing cells were incubated for 48 h
with growth media containing 1.0 mM PA conjugated to BSA (molar ratio 2:1) or BSA
100 µM	
  
alone. Cells were harvested, stained with ann V and PI, and the proportions of live cells
(Ann V- PI-), apoptotic cells (Ann V+ PI-) and dead cells (Ann V+ PI+) were determined by
flow cytometry. PA treated cells are compared to BSA for both control and EF shRNA
expressing cells. Data are expressed as mean ± SEM for 3 independent experiments, *p <
0.05. (C) Cell morphology of control shRNA or EF shRNA expressing cells and DMSO or
didemnin B treated wild-type HepG2 cells.
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knockdown of eEF1A-1 expression was not accompanied by resistance to palmitate-induced
cell death (Figure 3.10 B). However, EF shRNA expressing cells exhibited altered cell
morphology compared to control shRNA expressing cells (Figure 3.10 C). EF shRNA
expressing cells exhibited elongated projections extending from the cell body and enlarged

spherical structures, resembling vacuoles, within the cell body. This altered morphology was
not evident in wild-type HepG2 cells treated with didemnin B, thus these morphological
changes are not likely due to inhibition of the canonical elongation function of eEF1A-1 alone.
Taken together this data suggests that eEF1A-1 expression is induced in the livers of
obese mice as well as in HepG2 human hepatoma cells in response to excess palmitate, and
may participate in the process of lipotoxicity by mediating changes in protein synthesis related
to actin cytoskeleton remodeling that occur during cell stress.

	
  

	
  
	
  
	
  

4.0 DISCUSSION
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4.1 Summary of Results
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As much as 30% of the general population is currently affected with NAFLD, while the
prevalence in the morbidly obese is estimated at 75-92%, making this condition one of the
most common liver disorders worldwide (Trauner et al., 2010; Erickson, 2009). However, the
cause and progression of NAFLD is complex and not fully understood. Based on previous
findings identifying eEF1A-1 as a mediator of lipotoxic cell death in CHO cells and
cardiomyocytes, a similar role for this protein in hepatocytes was proposed. We hypothesized
that eEF1A-1 protein responds to lipid overload in hepatocytes and in the steatotic livers of
obese mice, and participates in the process of lipotoxicity. Furthermore, we proposed that the
mechanism of action of eEF1A-1 in lipotoxicity may involve its ability to regulate the actin
cytoskeleton. Our studies have revealed several key findings. 1) eEF1A-1 protein is induced,
in association with ER stress, in a mouse model of obesity with severe hepatic steatosis, and in
cultured hepatocytes exposed to excess saturated fatty acids. 2) A consequence of palmitate
overload in hepatocytes is increased colocalization of eEF1A-1 with the actin cytoskeleton and
decreased colocalization with the ER, followed by cell death, suggesting eEF1A-1 may
regulate changes in the actin cytoskeleton required for the progression of cell death. 3)
Inhibition of the elongation function of eEF1A-1 diminishes palmitate induced cell death,
while modest long-term inhibition of eEF1A-1 expression alters hepatocyte morphology with
no effect on palmitate-induced cell death, suggesting that the canonical function of eEF1A-1
may play a role in lipotoxicity.

	
  

	
  
	
  
	
  
4.2 eEF1A-1 in mouse models of obesity and hepatic steatosis
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Our data from diet induced and genetic models of obesity indicate that eEF1A-1 protein
content is increased under conditions of hepatic stress associated with severe steatosis and
insulin resistance. In addition to findings that eEF1A-1 protein is increased in steatotic mouse
myocardium (Borradaile et al., 2006a), changes in its expression have been reported in several
other obese and diabetic models. In an analysis of the dysregulated genes associated with
chronic hepatic steatosis, eEF1A-1 expression was increased in hepatocytes isolated from
obese insulin-resistant Zucker rats compared to lean littermates (Buqué et al., 2009).
Furthermore, others have shown that EF1A-1 expression is increased in the skeletal muscle of
both type 1 and type 2 diabetic patients, in skeletal muscle of streptozotocin-induced diabetic
rats (Reynet and Kahn, 2001), and in the renal cortex of diabetic rats (Al-Maghrebi et al.,
2005). These previous findings, along with our own observations that eEF1A-1 protein
expression is positively correlated with both liver triglyceride and plasma insulin, suggest
eEF1A-1 may play a role in the cellular pathways responsible for the pathogenesis of
metabolic syndrome.

4.3 eEF1A-1 as a response protein during saturated fatty acid induced ER stress and cell
death
In the present study, we show that eEF1A-1 responds to palmitate overload in
hepatocytes, consistent with previous findings in CHO cells and cardiomyocytes (Borradaile et
al., 2006a). Palmitate is the most common saturated fatty acid in our diet and cells were
treated with concentrations of fatty acids (up to 1.0 mM) that mimic those encountered in
pathophysiological conditions. We further found that eEF1A-1 protein was induced in cells
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treated with a combination of palmitate and oleate (40:60 molar ratio), which has not been

reported previously in any cell type. Of note, treatment with palmitate plus oleate was not
severe enough to induce ER stress or cell death, as was seen in palmitate treated HepG2 cells.
However, this combination is most similar to the fatty acid composition of North American
(Westernized) diets suggesting these results may have implications in vivo.

4.4 Subcellular localization of eEF1A-1 during fatty acid overload
eEF1A-1 is known to bind to and regulate polymerization of the actin cytoskeleton
(Shiina et al., 1994; Murray et al., 1996). Because the cytoskeleton undergoes dramatic
changes during apoptosis and cell death, we wanted to determine the subcellular localization
of eEF1A-1 under basal and lipid overload conditions in hepatocytes. Our initial findings
indicated relatively low colocalization of eEF1A-1 with the actin cytoskeleton under basal
conditions. Our images constructed from a z-series of optical sections indicate that, under
basal conditions, actin is primarily localized to the basolateral surface of the cell monolayer,
while eEF1A-1 is localized apically. These observations likely explain our difficulty in
acquiring confocal microscopy images in which the two proteins are present in the same
optical plane. Our finding that palmitate treatment increased colocalization of eEF1A-1 with
the actin cytoskeleton, combined with previous evidence that palmitate treatment can increase
polymerized actin content (Borradaile et al., 2006a) suggest that the response of eEF1A-1 to
saturated fatty acids in hepatocytes may involve regulation of cytoskeletal dynamics by
promoting actin polymerization. Similar effects on actin distribution are seen in cells treated
with H202, preceding cell death (Dalle-Donne et al., 2001; Zhu et al., 2005), conditions which
we showed also induce eEF1A-1 protein. Our finding that EF1A-1 localizes to the actin
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cytoskeleton and toward the basolateral surface of the cell during palmitate-induced stress may

also indicate increased localization at cell membrane surfaces that are in contact with the
surface of the cell culture plate. This is consistent with recent evidence indicating that eEF1A1 plays a role in anoikis through increased localization to the cell membrane (Itagaki et al.,
2012)
Others have reported changes in the localization of eEF1A-1 to actin in response to
external stimuli. Dharmawardhane et al. (1991) observed an increased incorporation of
eEF1A-1 into the actin cytoskeleton upon stimulation with the chemoattractant cAMP in the
actin-filament containing regions of the cell cortex and in the filopodia (Dharmawardhane et
al., 1991). However, this response was not involved in promoting cell death, as is likely the
case in our HepG2 cell experiments, but instead was involved with the extension of cell
surface projections.
Our finding that eEF1A-1 is mainly localized in the cytoplasmic compartment of
hepatocytes and colocalizes to the ER under basal conditions is consistent with findings in
other cell types (Minella et al., 1996; Chen et al., 2010). We further show here for the first
time that a decrease in colocalization of eEF1A-1 with the ER occurs following treatment with
palmitate. Taken together, these data, along with our results that significant palmitate-induced
cell death does not occur until 48 h, indicate that eEF1A-1 may mediate palmitate-induced cell
death by translocation toward the actin cytoskeleton to regulate changes in actin
polymerization required for the progression of cell death.
Although recent evidence from proteomic analyses of cytosolic lipid droplets suggests
eEF1A-1 associates with lipid droplets in various metabolic tissue cell types (Bartz et al.,
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2007; Zhang et al., 2011; Bouchoux et al., 2011; Ding et al., 2012), our findings do not

support these conclusions. Our confocal microscopy work indicates that eEF1A-1 does not
associate with or decorate cytosolic lipid droplets, as is seen with other lipid droplet-associated
proteins such as perilipin (Buers et al., 2011). This suggests that the association of eEF1A-1
with lipid droplets reported in previous studies may be found in specific cellular components,
such as the ER, that were co-purified with the lipid droplet fraction. Lipid droplet formation
originates at the ER, where it is believed that neutral lipids accumulate to form a lens between
the two leaflets of the phospholipid bilayer (Brasaemle and Wolins, 2012). The fact that
eEF1A-1 is highly localized to the ER makes it likely that biochemical isolation of lipid
droplets for proteomic analyses results in a preparation that is contaminated with some ER
localized proteins, including eEF1A-1.
4.5 Inhibition of eEF1A-1 elongation function and response to lipotoxicity
Although the peptide elongation function of eEF1A-1 is well characterized, it has not
been previously implicated in lipotoxicity. Didemnin B is a naturally occurring cyclic peptide
that inhibits protein synthesis by binding GTP-bound eEF1A-1 at the ribosome and preventing
ribosomal translocation (Ahuja et al., 2000; Marco et al., 2004). Thus, it specifically inhibits
the elongation function of eEF1A-1. Since its discovery in 1981, didemnin B has been to
show to have various antitumor, antiviral and immunosuppressive functions and was the first
compound isolated from a marine source to go into clinical trials for human diseases (Lee et
al, 2012).
Work from several laboratories has suggested that accumulation of unfolded proteins
in the ER and activation of the UPR itself is sufficient to cause hepatic steatosis (Imrie and
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Sadler, 2012). This suggests a possible disease scenario in which increased fatty acid flux

from adipose tissue to the liver initially induces ER stress, which in turn induces hepatic de
novo lipogenesis, which subsequently worsens hepatic ER stress, leading to the progression of
NAFLD. Our results show that treatment with palmitate in the presence of didemnin B
decreases palmitate-induced cell death, suggesting that the elongation function of eEF1A-1
may play a role in the lipotoxic response. Thus, it is possible that inhibition of protein
synthesis during palmitate overload may decrease the burden on the ER, which may prevent
activation of the UPR, ER stress response and subsequent activation of downstream apoptotic
pathways. This concept is supported by recent evidence that suggests alleviating ER stress and
the accumulation of misfolded proteins may serve as a possible therapeutic strategy for the
treatment NAFLD (Ibrahim et al., 2011). Small chemical chaperones such as glycerol or 4phenyl butyric acid (PBA) improve ER stress by increasing ER protein folding capacity and
facilitate the appropriate trafficking of misfolded proteins (Clark and Diehl, 2003). Treatment
of obese and diabetic mice with these compounds reduces ER stress, decreases hepatic
steatosis and improves liver function enzyme levels (Ozcan et al., 2006).

4.6 Knockdown of eEF1A-1 in hepatocytes and response to lipotoxicity
To determine whether knocking down eEF1A-1 expression could protect hepatocytes
from palmitate-induced cell death, we generated a stable population of HepG2 cells in which
eEF1A-1 expression was modestly reduced. We did not find that hepatocytes with reduced
eEF1A-1 expression were protected from lipotoxic cell death. This may be explained by the
limited extent of knockdown that was achieved (18% reduction). However, it is also possible
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that other, protective or adaptive functions of eEF1A-1 may be disrupted by reducing its
expression – functions which may not be disrupted by didemnin B.

eEF1A-1 is highly expressed in the liver and in other tissues with high rates of protein
synthesis and cell proliferation (lung, kidney, pancreas, placenta) (Knudsen et al., 1993).
Although eEF1A-1 is not rate-limiting for protein synthesis, it has roles in many other cellular
processes (Mateyak and Kinzy, 2010), therefore it is possible that hepatocytes with a greater
reduction of eEF1A-1 were not be viable for extended periods of time. Although no changes
in the cell death response to palmitate were observed in our EF shRNA expressing HepG2
population were observed, these cells exhibited an altered phenotype compared to control
shRNA expressing cells. Interestingly, Gross and Kinzy (2005) noted a difference in
morphology of cells in which the interaction between eEF1A-1 and actin was disrupted. Yeast
with mutations in the eEF1A-1 domain responsible for actin binding were shown to be larger
in size and exhibited pronounced elongated buds (Gross and Kinzy, 2005). Thus, it is possible
that even a small reduction in total protein expression may be sufficient to disrupt eEF1A-1actin interactions and result in altered cytoskeletal organization.
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Figure 4.1 Working model for the role of eEF1A-1 in hepatocyte response to saturated
fatty excess. During exposure to excess saturated fatty acids, cellular capacities to store them
as triglycerides (lipid droplets), to catabolize them through β-oxidation (mitochondria), or
secrete them in the form of VLDL particles are overwhelmed. Under basal conditions, the
majority of eEF1A-1 is localized to the ER and little is associated with the actin cytoskeleton.
Palmitate overload leads to mobilization of eEF1A-1 away from the ER and toward the actin
cytoskeleton to mediate changes in its structure, likely by promoting actin polymerization and
potentially actin synthesis, for the progression of cell death.
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Our working model for the role that eEF1A-1 plays in the stress response to saturated
fatty acid excess in hepatocytes is summarized in Figure 4.1. Based on this model, and our
evidence of increased eEF1A-1 protein in the livers of obese, leptin-deficient mice with severe
hepatic steatosis (ob/ob) mice, several future experiments are warranted.
To further support our evidence of the interaction between eEF1A-1 and the actin
cytoskeleton during palmitate overload, I would like to determine if eE1A-1 functions by
regulating cytoskeleton dynamics, as is seen in other cell types. To do so, I would disrupt the
interaction of eEF1A-1 with the actin cytoskeleton by transfecting cells with a construct
encoding domain III of eEF1A-1 (the dominant actin-binding domain). This construct is
expected to have a dominant-negative action on the eEF1A-1-actin interaction. To induce lipid
overload and cell death, cells will be treated with palmitate and cell death will be assessed by
flow cytometry.
Based on our results that treatment with didemnin B reduces palmitate-induced cell
death in HepG2 cells, future studies should be directed towards testing the effectiveness of
didemnin B in improving hepatocyte damage in mouse models of NAFLD. The results
presented in this thesis indicate that eEF1A-1 expression is increased in the livers of leptin
deficient ob/ob mice and these animals exhibited the most severe form of hepatic steatosis and
ER stress. Furthermore, ob/ob mice are a well-characterized model of NAFLD (Anstee and
Goldin, 2006). Thus, I would select this model for subsequent didemnin B experiments.
Previous work has demonstrated that didemnin B is highly concentrated in the livers of mice
following intraperitoneal administration (Beasley et al., 2005). To determine if ER stress and
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hepatocyte damage is attenuated in the livers of these mice treated with didemnin B, liver
samples will be analyzed for GR78 expression, PERK phosphorylation and JNK activity.
These markers of ER stress are consistently exhibited in ob/ob mice (Ozcan et al., 2004).
Serum measurements of ALT and AST activity will be used as additional indicators of liver
damage.
The liver is composed of hepatocytes and non-parenchymal cells, which include

kupffer cells, sinusoidal endothelial cells and hepatic stellate cells (Bian and Ma, 2012).
Hepatic stellate cells play a key role in the hepatic fibrogenesis associated with NASH. Under
normal conditions, hepatic stellate cells are maintained in a quiescent state but can undergo a
phenotypic transition to become activated in response to liver injury. These cells are the major
source of the excessive extracellular matrix production that characterizes fibrotic liver (Viera
and Nato, 2006). It is possible that eEF1A-1 may play a role in the progression to fibrosis
during the process of hepatic stellate cell activation. Future experiments in which expression
of eEF1A-1 in hepatic stellate cells is reduced in obese mice may give us further insight into
the role this protein plays in the progression of NAFLD.
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February 18, 2010
*This is the Original Approval for this protocol*
*A Full Protocol submission will be required in 2014*
Dear Dr. Borradaile:
Your Animal Use Protocol form entitled:

Liver Function During Obesity and Type 2 Diabetes
Funding Agency Canadian Lipoprotein Conference
has been approved by the University Council on Animal Care. This approval is valid from February 18, 2010 to
February 28, 2011. The protocol number for this project is 2010-018.
1. This number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this number.
3. If no number appears please contact this office when grant approval is received.
If the application for funding is not successful and you wish to proceed with the project, request that an internal
scientific peer review be performed by the Animal Use Subcommittee office.
4. Purchases of animals other than through this system must be cleared through the ACVS office. Health
certificates will be required.
ANIMALS APPROVED FOR 4 Years

Species

4 Year Total
Numbers
Estimated as
Required

List All Strain(s)

Age / Weight

Mouse

240

C57Bl/6/ ob/ob

4-5 weeks

REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in this protocol, are familiar
with the contents of this document.

The holder of this Animal Use Protocol is responsible to ensure that all associated safety components
(biosafety, radiation safety, general laboratory safety) comply with institutional safety standards and
have received all necessary approvals. Please consult directly with your institutional safety officers.

c.c. Approval

- N. Borradiale, W. Lagerwerf

The University of Western Ontario
Animal Use Subcommittee / University Council on Animal Care
Health Sciences Centre, ● London, Ontario ● CANADA – N6A 5C1
PH: 519-661-2111 ext. 86770 ● FL 519-661-2028 ● www.uwo.ca / animal

Page 1 of 1

AUP Number: 2011-044
PI Name: Borradaile, Nica M
AUP Title: Vascular Regeneration After Increased Nad+ Availability In Diet Induced Metabolic
Syndrome
Approval Date: 03/09/2012
Review Date: 03/09/2013
Expiry Date: 03/09/2016
Official Notice of Animal Use Subcommittee (AUS) Approval: Your new Animal Use Protocol
(AUP) entitled "Vascular Regeneration After Increased Nad+ Availability In Diet Induced Metabolic
Syndrome" has been APPROVED by the Animal Use Subcommittee of the University Council on
Animal Care. This approval, although valid for four years, and is subject to annual Protocol
Renewal.2011-044::1
1. This AUP number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this AUP number.
3. Purchases of animals other than through this system must be cleared through the ACVS
office. Health certificates will be required.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety
components (biosafety, radiation safety, general laboratory safety) comply with institutional safety
standards and have received all necessary approvals. Please consult directly with your institutional
safety officers.
Submitted by: Copeman, Laura
on behalf of the Animal Use Subcommittee
University Council on Animal Care

file://C:\Documents and Settings\nborrad\Local Settings\Temp\XPgrpwise\4F59F08FMe...

09/03/2012

Page 1 of 1

2010-018::3:
AUP Number: 2010-018
AUP Title: Liver function during obesity and type 2 diabetes
Yearly Renewal Date: 03/01/2013
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2010-018 has been approved, and
will be approved for one year following the above review date.

1. This AUP number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this AUP number.
3. Purchases of animals other than through this system must be cleared through the ACVS
office.
Health certificates will be required.
REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in
this protocol, are familiar with the contents of this document.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety
components (biosafety, radiation safety, general laboratory safety) comply with
institutional safety standards and have received all necessary approvals. Please consult
directly with your institutional safety officers.
Submitted by: Kinchlea, Will D
on behalf of the Animal Use Subcommittee
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